Discovery
-
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko
6/5/2024
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA™ therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD.
-
Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams
11/6/2024
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial.
-
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.
7/4/2024
KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types.
-
The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault
7/18/2023
Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as how the CGT sector is benefiting from RNA, AI, and synthetic biology.
-
Inside A Dopamine-Restoring Cell Therapy For PD With BlueRock Therapeutics' Dr. Amit Rakhit
12/4/2024
On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rakhit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments, the limitations of current PD medications, and much more.
-
Harnessing the Power of Cord Blood Tregs with Cellenkos' Dr. Simrit Parmar
3/12/2025
In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases.
-
The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan
1/15/2025
Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.
-
Pioneering Next-Gen TCR Therapies In Solid Tumors With Neogene Therapeutics' Carsten Linnemann, Ph.D.
10/9/2024
Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers.
-
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
1/29/2025
Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors.
-
Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali
2/11/2025
In this episode, Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insights on Tenaya's gene therapy platform, their in-house manufacturing capabilities, and the potential impact of their therapies on prevalent heart conditions.